Observational cohort of patients with worsening idiopathic pulmonary fibrosis
Official title: Pulmonary Fibrosis Biomarkers During Exacerbation
Run by University Hospital, Gentofte, Copenhagen · NCT04442711 · Data updated 2026-11-12
This study is tracking patients with worsening idiopathic pulmonary fibrosis who need to be hospitalized to see how different biological markers relate to their health and quality of life over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University Hospital, Gentofte, Copenhagen Academic / other |
| Locations | 1 site (Hellerup, Copenhagen) |
| Status | Recruiting |
| Started | June 13, 2020 |
| Main results expected | December 1, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | December 22, 2023 |
| Trial ID | NCT04442711 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have been diagnosed with IPF and are experiencing an exacerbation requiring hospitalization.
✕Probably not a fit
Patients who are unable to provide informed consent or those not experiencing an exacerbation of respiratory symptoms will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study follows patients with idiopathic pulmonary fibrosis (IPF) who experience exacerbations requiring hospitalization. It aims to collect clinical and biological data to assess the diagnostic and prognostic value of various biomarkers during these exacerbations. Patients are recruited within 24 hours of hospital admission, and their clinical outcomes and quality of life are also evaluated over a longitudinal follow-up period of up to five years. The study builds on the existing PFBIO cohort to enhance understanding of IPF exacerbations.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment strategies for patients experiencing exacerbations of IPF.
How similar studies have gone: While this study builds on existing cohorts, the specific focus on exacerbations in IPF patients is a relatively novel approach that has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Admitted with an increase in respiratory symptoms * Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA * Age at least 18 years Exclusion Criteria: * Unable to provide informed consent
Where it's running
-
Herlev and Gentofte Hospital
Hellerup, Copenhagen, Denmark Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
New IPF drug ORJ-001 tested in adults with IPF
A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.
-
Nalbuphine ER for IPF-related chronic cough
This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.
-
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.
-
Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs
This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.
-
Rentosertib by mouth for people with idiopathic pulmonary fibrosis
This is a randomized, placebo-controlled test to see if Rentosertib helps adults with idiopathic pulmonary fibrosis when taken as a pill.
-
Inhaled nintedanib powder for IPF in adults
This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.